University of Liverpool and MeMed

MeMed BV® is the first FDA-cleared and CE-Marked host-immune response assay for accurately distinguishing bacterial and viral infections in just 15 minutes in children and adults.
MeMed BV’s performance has been validated in multi-national, blinded clinical studies and real world settings enrolling >20,000 subjects in Europe, Israel and the United States. These studies consistently demonstrated high performance across settings, ages, and syndromes.
MeMed Key® is a compact platform that runs highly sensitive protein measurements that previously could only be done on large, expensive lab equipment. Together, MeMed Key and BV help physicians make better decisions when managing acute infections.